Tryptamine compositions and methods
AssigneeCybin IRL Limited
InventorsKenneth L. Avery, James He Huang, Alex Nivorozhkin, Pradip M. Pathare, Mohammed I. Shukoor
Life of this patent
Estimating the term…
Abstract
There are disclosed pharmaceutically acceptable salts of tryptamine compounds, the use of such salt forms in the treatment of diseases associated with a serotonin 5-HT2 receptor, pharmaceutical compositions such as those adapted for inhalation administration containing the salt forms, methods of delivering the pharmaceutically acceptable salt forms (e.g., via inhalation), and methods of treating diseases or disorders associated with a serotonin 5-HT2 receptor, such as central nervous system (CNS) disorders or psychological disorders, with the salt forms. (Formula (I))
Claims36
A pharmaceutically acceptable salt of a compound of Formula (I), or a solvate thereof,
- wherein:
- X1 and X2 are deuterium,
- Y1 and Y2 are deuterium,
- R2, R4, R5, R6, and R7 are independently hydrogen or deuterium, and
- R8 and R9 are independently selected from the group consisting of —CH3, —CDH2, —CD2H, and —CD3.
2-6. (canceled)
(canceled)
13-15. (canceled)
17-20. (canceled)
30-31. (canceled)
33-35. (canceled)
37-53. (canceled)
A pharmaceutical composition, comprising:
- an active salt mixture comprising (i) a pharmaceutically acceptable salt of 2-(1H-indol-3-yl)-N,N-bis(methyl-d3)ethan-1-amine-1,1,2,2-d4 (I-8), and (ii) a pharmaceutically acceptable salt of one or more of 2-(1H-indol-3-yl)-N,N-bis(methyl-d3)ethan-1-amine-1,2,2-d3 (I-10) and/or 2-(1H-indol-3-yl)-N,N-bis(methyl-d3)ethan-1-amine-1,1,2-d3 (I-11);
- and
- a pharmaceutically acceptable vehicle.
64-66. (canceled)
Dependencies are inferred from the claim text.